What is the clinical evidence from this study?

Study design: Review. Population: Diabetic Neuropathy. Intervention: Management of Diabetic Neuropathy.

What does this research mean for the field?

Management of diabetic neuropathy remains challenging due to a lack of targeted treatments, and opioids are not recommended for painful distal symmetric polyneuropathy. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

August 1, 2018Diabetes SpectrumOpen Access

Update on the Management of Diabetic Neuropathy

View Full Paper

Ask AI

Bookmark

Key result

Diabetic neuropathy management centers on glycemic control, lifestyle modification, and targeted pharmacotherapy for pain.

Population

Patients with diabetic neuropathy, specifically distal symmetric polyneuropathy and cardiovascular autonomic…

Design

Review

Authors

LALynn AngUniversity of Michigan NCNathan CowdinUniversity of Michigan KMKara Mizokami‐StoutVA Ann Arbor Healthcare System

Discussion

Member takes

Implication

Supports non-opioid agents and glycemic prevention in diabetic neuropathy; leaves open prospective validation of autonomic neuropathy screening.

Structured PICO

Population

Patients with diabetic neuropathy, specifically distal symmetric polyneuropathy (DSPN) and cardiovascular autonomic neuropathy (CAN)

Intervention

Management and screening strategies, including avoidance of opioids for painful DSPN

This review emphasizes the clinical diagnosis of diabetic neuropathies, the need to screen for cardiovascular autonomic neuropathy, and strongly advises against using opioids for painful neuropathy.

Limitations

Lack of treatment options that effectively target the natural history of diabetic neuropathies or reverse their course once established
Inconsistencies among various available guidelines for neuropathic pain treatment
Potential publication bias given that many trials with negative results may not have been published

Cite This Study

Ang et al. (2018) conducted a review in Diabetic Neuropathy. Management of Diabetic Neuropathy was evaluated. Management of diabetic neuropathy relies on prevention through glycemic control and lifestyle modifications, alongside symptomatic treatment of neuropathic pain using agents like pregabalin or duloxetine.

synapsesocial.com/papers/6a1ecdea989adebfe89a9bba https://doi.org/10.2337/ds18-0036

View Full Paper

Ask AI

Bookmark

Implication

Supports non-opioid agents and glycemic prevention in diabetic neuropathy; leaves open prospective validation of autonomic neuropathy screening.

Update on the Management of Diabetic Neuropathy

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Update on the Management of Diabetic Neuropathy

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider